Protara Therapeutics, Inc. (NASDAQ:TARA) Receives $26.25 Consensus Target Price from Brokerages

Protara Therapeutics, Inc. (NASDAQ:TARA) has earned an average recommendation of “Moderate Buy” from the eight research firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $26.25.

A number of analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating on shares of Protara Therapeutics in a report on Wednesday, May 20th. Wall Street Zen cut Protara Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. JPMorgan Chase & Co. cut their price objective on Protara Therapeutics from $27.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, May 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Protara Therapeutics in a research note on Friday, July 17th. Finally, Oppenheimer lifted their target price on Protara Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a report on Wednesday, May 20th.

Hedge Funds Weigh In On Protara Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Corient Private Wealth LP purchased a new position in Protara Therapeutics in the 2nd quarter worth about $41,000. Persistent Asset Partners Ltd purchased a new stake in Protara Therapeutics during the fourth quarter valued at about $57,000. AXQ Capital LP acquired a new position in shares of Protara Therapeutics in the fourth quarter worth about $58,000. The Manufacturers Life Insurance Company acquired a new position in shares of Protara Therapeutics in the fourth quarter worth about $59,000. Finally, Empery Asset Management LP purchased a new position in shares of Protara Therapeutics in the fourth quarter worth approximately $68,000. Institutional investors and hedge funds own 38.13% of the company’s stock.

Protara Therapeutics Trading Up 1.0%

Shares of NASDAQ TARA opened at $3.86 on Friday. Protara Therapeutics has a twelve month low of $3.02 and a twelve month high of $7.82. The company has a market capitalization of $228.13 million, a price-to-earnings ratio of -2.86 and a beta of 1.50. The firm has a 50-day moving average of $4.02 and a two-hundred day moving average of $4.78.

Protara Therapeutics (NASDAQ:TARA) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.03). As a group, research analysts predict that Protara Therapeutics will post -1.48 earnings per share for the current year.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.